Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates
Aurum Biosciences Ltd is a UK based clinical stage biopharmaceutical company developing novel oxygen carriers for use as therapeutics and diagnostics, initially for Acute Ischaemic Stroke (AIS) and Inflammation Imaging. Follow-on indications include heart disease, cardiac arrest, oncology, spinal cord injury (SCI), and traumatic brain injury (TBI).
Centauri Therapeutics is an immunotherapy company currently focused on infectious diseases and oncology. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.
Centrix Pharma Solutions is a UK-based, development-focused CDMO specialising in early-stage drug product development and clinical trial manufacturing for orally delivered small molecules.
Built on the heritage of Custom Pharma Services (established in 1979), Centrix was created to support the most critical stages of drug development. guiding innovative biotech companies from concept to clinic with confidence. Our approach is rooted in deep pharmaceutical science, patient-centric design, and proactive risk management, ensuring drug products are designed right from the start.
We work as a genuine partner to our clients, combining formulation development, analytical strategy, and GMP clinical manufacturing within an integrated, agile model. By aligning product and patient requirements early, we help reduce rework, control timelines, and de-risk progression into first-in-human and later-phase clinical studies.
Centrix is trusted by early-stage and virtual biotech companies seeking flexibility, transparency, and direct access to experienced scientists. With a focus on collaboration and scientific integrity, we don’t just deliver services. we help turn promising molecules into patient-ready medicines.
Our proprietary platform selectively deliver drugs to damaged elastin. We already have proof of concept in cardiovascular calcification, aneurysms and emphysema animal models.Elastrin Therapeutics Inc. is a biotech startup set to rejuvenate cardiovascular diseases. Our mission is to develop innovative therapies that target the root causes of cardiovascular conditions, providing new hope for patients and their families. We are dedicated to advancing the field of biotechnology through cutting-edge research and collaborative partnerships.
Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.
Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.
The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.
As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.
